Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Non-Current Liabilities (2016 - 2020)

Vistagen Therapeutics' Other Non-Current Liabilities history spans 9 years, with the latest figure at $5.9 million for Q4 2020.

  • For Q4 2020, Other Non-Current Liabilities rose 26.4% year-over-year to $5.9 million; the TTM value through Dec 2020 reached $5.9 million, up 26.4%, while the annual FY2020 figure was $5.0 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2020 was $5.9 million at Vistagen Therapeutics, up from $5.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.9 million in Q4 2020 and bottomed at $946000.0 in Q2 2016.
  • The 5-year median for Other Non-Current Liabilities is $3.2 million (2018), against an average of $3.4 million.
  • The largest YoY upside for Other Non-Current Liabilities was 343.51% in 2016 against a maximum downside of 5.4% in 2016.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.3 million in 2016, then soared by 75.05% to $2.3 million in 2017, then surged by 47.43% to $3.5 million in 2018, then soared by 35.59% to $4.7 million in 2019, then rose by 26.4% to $5.9 million in 2020.
  • Per Business Quant, the three most recent readings for VTGN's Other Non-Current Liabilities are $5.9 million (Q4 2020), $5.7 million (Q3 2020), and $5.3 million (Q2 2020).